Moderna CEO shares bold new vision: 15 new products and 50 new clinical candidates in five years

Ryan Cross

Senior Science Correspondent

If there’s one thing that Moderna CEO Stéphane Bancel wants to make abundantly clear, it’s that his company and its mRNA technology are not a one-hit wonder.

On Wednesday morning, Moderna announced its intentions to launch up to 15 new products and advance up to 50 mRNA medicines into clinical trials over the next five years — an audacious goal for a biotech best known for its only product: a Covid-19 vaccine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Moderna CEO shares bold new vision: 15 new products and 50 new clinical candidates in five years

Ryan Cross

Senior Science Correspondent

Unlock this article instantly by becoming a free subscriber.

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

AstraZeneca pulls Covid-19 vaccine globally as the pharma sees 'no future commercial demand'

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Medical Affairs: The Critical Link Between Science, Physicians and Patients

Mod­er­na CEO shares bold new vi­sion: 15 new prod­ucts and 50 new clin­i­cal can­di­dates in five years

Ryan Cross

Senior Science Correspondent

Unlock this article instantly by becoming a free subscriber.

Af­ter eight years with Sanofi, Frank Nes­tle de­parts as CSO, glob­al head of re­search

In­side CVS Care­mark’s move that broke Hu­mi­ra’s hold on the mar­ket

'Big­ger, faster, bet­ter': Iso­mor­phic, Deep­Mind un­veil Al­phaFold 3, go­ing be­yond pro­tein pre­dic­tions

As­traZeneca pulls Covid-19 vac­cine glob­al­ly as the phar­ma sees 'no fu­ture com­mer­cial de­mand'

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

Moderna CEO shares bold new vision: 15 new products and 50 new clinical candidates in five years

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

AstraZeneca pulls Covid-19 vaccine globally as the pharma sees 'no future commercial demand'

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Medical Affairs: The Critical Link Between Science, Physicians and Patients